CORRECTIONS

Journal Corrections

The January 20, 2010, article by Cortes et al, entitled “Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study” (J Clin Oncol 28:424-430, 2010), contained an error.

In Figure 2, the first four plots on the x-axis were labeled as 0, 12, 15, 18 months, and should have been 0, 3, 6, 9 months. *Journal of Clinical Oncology* apologizes to the authors and readers for the mistake.

DOI: 10.1200/JCO.2010.29.6988

The February 1, 2010, article by Chrischilles et al, entitled “Adverse Events Among the Elderly Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer” (J Clin Oncol 28:620-627, 2010), contained errors.

The authors’ affiliations were inadvertently listed in the Acknowledgment section instead of the sidebar. In addition,

the corresponding author’s e-mail address was incorrect and should have been: e-chrischilles@uiowa.edu.

The online version has been corrected in departure from the print. *Journal of Clinical Oncology* apologizes to the authors and readers for the mistakes.

DOI: 10.1200/JCO.2010.29.6996

Author Corrections

The February 10, 2010, article by Palumbo et al, entitled “Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients” (J Clin Oncol 28:800-807, 2010), contained an error.

In Figure 3B, the values for high and low risk were inadvertently transposed. The correct values for high risk are: 27 (at 0

month), 26 (at 6 months), 24 (at 12 months), 13 (at 18 months), and 6 (at 24 months). The correct values for low risk are: 47 (at 0 month), 41 (at 6 months), 25 (at 12 months), 17 (at 18 months), and 11 (at 24 months).

The authors apologize to the readers for the mistake.

DOI: 10.1200/JCO.2010.29.6962